Background/aims: To investigate a reported outbreak of presumed hepatitis E virus (HEV) infection in a Korean food manufacturing facility and to explore the association between anti-HEV immunoglobulin M (IgM) positivity and coronavirus disease 2019 (COVID-19) infection or vaccination.
Methods: Twenty-four cases of anti-HEV IgM positivity were reported among 646 workers at the facility in 2022. An epidemiological investigation was conducted, comprising HEV-RNA testing of blood and environmental samples, analysis of group meal records, and an association between anti-HEV IgM positivity and confirmed COVID-19 infection or vaccination.
Results: All 24 patients were asymptomatic, with cases spread sporadically across the facility. HEV RNA was not detected in the serum or environmental samples. Four out of 340 meals (1.2%) showed a significantly higher proportion of anti-HEV positivity in each meal intake group than in the non-intake group on certain days. Although the cumulative rate of COVID-19 infection showed no difference, the anti-HEV IgM positive group showed significantly higher proportions of >2 doses of COVID-19 vaccination (83.3% vs 48.7%, p=0.021), vaccination within 90 days (45.8% vs 19.7%, p=0.008), and having the Moderna vaccine administered as the last vaccine (75.0% vs 14.5%, p<0.001) than those of the anti-HEV negative group. In four multivariable models, three or more COVID-19 vaccinations and the Moderna vaccine as the last vaccine were consistently associated with anti-HEV IgM positivity, while the specific day group meal intake was also a significant factor.
Conclusions: This epidemiological investigation showed that anti-HEV IgM positivity may occur as a false-positive result related to COVID-vaccination over three times and use of the Moderna vaccine, although a portion of true HEV infection may not be excluded.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096911 | PMC |
| http://dx.doi.org/10.5009/gnl230098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case-control and bias indicator study.
Lancet Infect Dis
January 2025
Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland; Médecins Sans Frontières, Geneva, Switzerland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland. Electronic address:
Background: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalent. Although a recombinant vaccine, Hecolin, is available, it has not been used to control outbreaks. The licensed three-dose regimen might pose challenges for it to be an impactful outbreak control tool.
View Article and Find Full Text PDFIncidence and risk factors of hepatitis E virus infection in women with gynecological tumors in Eastern China.
PeerJ
December 2024
Department of Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Recently, there has been increasing interest in the exploration of the association between the hepatitis E virus () infection and malignancies; however, epidemiological data for infection among women with a gynecological tumors (GT) are limited. Herein, we investigated the correlation between and GT in Chinese women.
Methods: We recruited 452 women diagnosed with a primary GT and 452 healthy volunteers to investigate the possible routes and risk factors for infection.
Case report: Malaria and hepatitis E coinfection-first experience with such imported entity in Serbia.
Front Med (Lausanne)
December 2024
Department of Infectious Diseases and Epidemiology, Faculty of Medicine, University of Niš, Niš, Serbia.
Acute hepatitis E virus (HEV) and malaria are not rare infections in tropical countries; however, in the European continent, such imported entity has not been reported up to now. Herein, we report a 24-year-old male suffering from malaria and hepatitis E, who was admitted with acute hepatic failure dark colored urine, followed by coagulation and inflammation parameters increase. Blood smear analysis revealed the presence of , while serological tests revealed anti-HEV IgM antibodies.
View Article and Find Full Text PDFSeroprevalence patterns of viral hepatitis B, C, and E among internally displaced persons in Borno State, Nigeria.
IJID Reg
December 2024
Department 1: Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Objectives: Following the outbreak of hepatitis E in camps for internally displaced persons (IDPs) in Borno State in 2017, we assessed hepatitis B, C, and E biomarkers (hepatitis B surface antigen [HBsAg], anti-HBC, anti-hepatitis E virus [HEV] immunoglobulin [Ig] G, and anti-HEV IgM) among IDPs in three camps in Borno State, Nigeria, to determine seroprevalence rates in these understudied populations.
Methods: A total of 454 IDPs, including pregnant women and breastfeeding mothers, were randomly selected, and their demographic, clinical, and epidemiological data were collected. Blood samples were tested for HBsAg and anti-hepatitis C virus (HCV) using rapid tests, anti-HEV IgM, and anti-HEV IgG using enzyme-linked immunosorbent assay.
Seroprevalence of hepatitis E virus infection in blood donors from Piauí State, Northeast Brazil.
Braz J Infect Dis
November 2024
Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Hepatites Virais, Rio de Janeiro, RJ, Brazil. Electronic address:
Article Synopsis
- - A study was conducted in Piauí State, Brazil, to assess the prevalence of Hepatitis E Virus (HEV) among blood donors, involving 890 participants with a median age of 33.4 years, mostly males from the Mid-Northern region.
- - Blood samples were tested for anti-HEV IgG and IgM antibodies using advanced techniques, alongside PCR testing for HEV RNA.
- - The findings showed low prevalence rates for anti-HEV IgG (1.35%) and IgM (0.11%), with no HEV-RNA detected, indicating minimal HEV infection among blood donors in the area.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!